Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

LESSONS LEARNED. The triple combination chemotherapy of SOXIRI (S‐1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma was an effective treatment that appeared to be better tolerated than the widely used FOLFIRINOX regimen. SOXIRI regimen may provide an alternativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Akahori, Takahiro, Sho, Masayuki, Yanagimoto, Hiroaki, Satoi, Sohei, Nagai, Minako, Nishiwada, Satoshi, Nakagawa, Kenji, Nakamura, Kota, Yamamoto, Tomohisa, Hirooka, Satoshi, Yamaki, So, Ikeda, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656520/
https://www.ncbi.nlm.nih.gov/pubmed/30679316
http://dx.doi.org/10.1634/theoncologist.2018-0900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656520/
https://www.ncbi.nlm.nih.gov/pubmed/30679316
http://dx.doi.org/10.1634/theoncologist.2018-0900

Ejemplares similares